The Defense Logistics Agency Troop Support is seeking sources capable of providing the Japanese Encephalitis Vaccine (JEV).  DLA Troop Support is contemplating awarding a one-year indefinite quantity contract for the JEV.  The estimated annual quantity to be ordered is 150,000 doses.  However, the quantity may increase or decrease as the Services requirements change.

The vaccine shall be purified, inactivated, Vero Cell culture derived, contain no stabilizers, Thimerosal/Preservative free, Latex free, licensed by the Food and Drug Administration (FDA), suitable for intramuscular administration and intended for active immunization against Japanese Encephalitis disease.  The vaccine shall be a sterile 0.5 ml suspension in a pre-filled syringe (Type 1 glass) with a plunger stopper (chlorobutyl elastomer) with or without a separate needle.  The vaccine must be approved by the FDA for administration to persons 2 months of age and up.  

Must have FDA approval to sell the JEV before award of the contract.

If your firm currently manufactures or distributes the JEV, please provide information with respect to the following:

a) Place of manufacture
b) Estimated annual capacity
c) FDA registration
d) Product name and description including description of any special features
e) Current unit sale price
f) Estimated inventory level and storage requirements

*** NEW PRODUCTS UNDER DEVELOPMENT***

For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc.  Firms and organizations that currently develop or manufacture the JEV or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.

Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the JEV.  All information submitted shall remain with the U.S. Government and will not be returned.  It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.

This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement.  

Your response to this RFI may be submitted electronically in pdf format and emailed to [email protected].